CN112618644A - Traditional Chinese medicine compound composition for treating ovarian reserve function decline and preparation method thereof - Google Patents
Traditional Chinese medicine compound composition for treating ovarian reserve function decline and preparation method thereof Download PDFInfo
- Publication number
- CN112618644A CN112618644A CN202011568244.1A CN202011568244A CN112618644A CN 112618644 A CN112618644 A CN 112618644A CN 202011568244 A CN202011568244 A CN 202011568244A CN 112618644 A CN112618644 A CN 112618644A
- Authority
- CN
- China
- Prior art keywords
- parts
- root
- chinese medicine
- traditional chinese
- compound composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/36—Skin; Hair; Nails; Sebaceous glands; Cerumen; Epidermis; Epithelial cells; Keratinocytes; Langerhans cells; Ectodermal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/40—Cornaceae (Dogwood family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
- A61K36/725—Ziziphus, e.g. jujube
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/746—Morinda
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Developmental Biology & Embryology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine compound composition for treating ovarian reserve function decline, which comprises the following components in parts by weight: 25-30 parts of prepared rehmannia root, 10-30 parts of angelica, 10-30 parts of white peony root, 10-15 parts of cornus officinalis, 5-15 parts of eucommia bark, 10-25 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 5-10 parts of teasel root, 15-20 parts of honey-fried licorice root, 15-20 parts of astragalus, 10-20 parts of codonopsis pilosula, 5-15 parts of Chinese date, 5-10 parts of donkey-hide gelatin, 10-15 parts of morinda officinalis, 10-15 parts of dodder, 10-30 parts of achyranthes root, 10-20 parts of Chinese yam and 10-15 parts of gorgon fruit. The invention also discloses a preparation method of the traditional Chinese medicine compound composition for treating the ovarian reserve function decline, which effectively solves the problem of ovarian reserve function decline.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicine formulas, and particularly relates to a traditional Chinese medicine compound composition for treating ovarian reserve function decline and a preparation method thereof.
Background
The follicle mainly consists of an oocyte, granular cells and theca cells which surround the oocyte, and the development of the follicle is a complex process which mainly comprises the following stages: forming an oogonium cell by mitosis after the primordial germ cells migrate to the genital ridge; the oogonium is proliferated through mitosis to enter a double-line phase to form a primary oocyte; primary oocytes are surrounded by a monolayer of flat promyelocytic cells and segregate to form primordial follicles (the only way to reserve ovary); the monolayer of flat pre-granulosa cells are differentiated into a monolayer of cubic granulosa cells to wrap the primary oocyte to form a primary follicle, and the granulosa cells secrete mucopolysaccharide to form a zona pellucida to wrap the oocyte; granulosa cells of the primary follicle proliferate, the follicle enlarges, forms a secondary follicle, and has the ability to synthesize steroid hormones; under the combined action of follicle stimulating hormone and estrogen, the granulosa cells continue to proliferate and secrete follicular fluid to fuse into a follicular cavity to form antral follicles; the follicular fluid increases sharply in 5-6 days of ovulation period, the follicular cavity enlarges, the follicular volume increases and moves to the surface of ovary to protrude, and the preovulatory follicle is formed.
The reduction of the ovary reserve function refers to the reduction of the ability of ovaries to produce ova and the reduction of the quality of follicles, which cause the reduction of the fertility and the disorder of reproductive endocrine function of women, and can further develop into premature ovarian failure. The main symptoms and test indicators of the ovarian reserve function decline include: fertility decline, infertility; the menstrual cycle is shortened, and the menstrual flow is reduced; perimenopausal symptoms such as hot flashes, night sweats, reduced sexual function, etc.; FSH (follicle stimulating hormone) > 10mlU/mL or FSH/LH (Luteinizing hormone) is more than 2; the anti-mullerian hormone is less than 2ng/ml, and the number of basic antral follicles is less than 5.
At present, clinical ovarian function improvement is mainly started from the aspects of improving recruitment of primordial follicles, promoting maturation of oocytes, resisting oxidation and the like, and the representative medicines comprise estradiol valerate, dehydroepiandrosterone, growth hormone, coenzyme Q10 and the like; the traditional Chinese medicine treats the descending of the ovarian reserve function mostly from the treatment of kidney deficiency, and the pathology is considered that congenital endowment deficiency or sexual disorder damages kidney qi, thoroughfare and conception vessel deficiency, uterine vessels are out of warm, and cannot control essence to become pregnancy; or damage the true yang in the kidney, decline of the fire from the gate of life, inability to transform qi and move water, cold-dampness retention in the Chong and ren channels, dampness accumulation in the uterus, inability to control sperm and become pregnancy; or during menstruation, the patient feels cold when wading, the kidney is injured by cold evil, the thoroughfare and conception vessels are injured, and the patient cannot take semen to become pregnant when the patient is cold; or the sexual intercourse is irregular, the essence and blood are consumed, the kidney yin is damaged, so that the blood of Chong and ren meridians is less, the semen can not be coagulated to become pregnant, even the yin blood is insufficient, the yin deficiency and the internal heat, the heat is accumulated in the Chong and ren meridians, the heat disturbs the blood sea, so that the semen can not be coagulated to become pregnant, and the traditional Chinese medicine compound with good treatment effect on the ovarian reserve function decline is still lacked at present.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a traditional Chinese medicine compound composition for treating ovarian reserve function decline and a preparation method thereof, which effectively solve the problem that the traditional Chinese medicine compound has poor treatment effect on ovarian reserve function decline.
In order to achieve the purpose, the technical scheme adopted by the invention for solving the technical problems is as follows:
the traditional Chinese medicine compound composition for treating ovarian reserve function decline is provided, and comprises the following components in parts by weight: 25-30 parts of prepared rehmannia root, 10-30 parts of angelica, 10-30 parts of white peony root, 10-15 parts of cornus officinalis, 5-15 parts of eucommia bark, 10-25 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 5-10 parts of teasel root, 15-20 parts of honey-fried licorice root, 15-20 parts of astragalus, 10-20 parts of codonopsis pilosula, 5-15 parts of Chinese date, 5-10 parts of donkey-hide gelatin, 10-15 parts of morinda officinalis, 10-15 parts of dodder, 10-30 parts of achyranthes root, 10-20 parts of Chinese yam and 10-15 parts of gorgon fruit.
Preferably, the traditional Chinese medicine compound composition for treating ovarian reserve function decline is provided, and comprises the following components in parts by weight: 30 parts of prepared rehmannia root, 15 parts of Chinese angelica, 15 parts of white paeony root, 15 parts of cornus officinalis, 6 parts of eucommia bark, 15 parts of largehead atractylodes rhizome, 9 parts of tuckahoe, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus root, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of dodder, 10 parts of twotooth achyranthes root, 15 parts of Chinese yam and 10 parts of gordon euryale seed.
In the scheme, the prepared rehmannia root, the astragalus root, the codonopsis pilosula and the gorgon fruit are used as monarch drugs in the formula, so that the effects of tonifying kidney, replenishing essence and marrow, tonifying qi, nourishing blood and promoting the production of body fluid are achieved, and the effects of consolidating body resistance, replenishing essence, cultivating primordial qi and assisting pregnancy are achieved;
chinese angelica, white paeony root, cornus officinalis, donkey-hide gelatin, morinda officinalis, dodder and the like are used as ministerial drugs, and the Chinese angelica-donkey-hide gelatin-Chinese medicinal composition has the effects of tonifying kidney and supporting yang and has the effect of strengthening yang; tonifying blood and yin, regulating thoroughfare and conception vessels blood, tonifying liver and kidney yin, paying more attention to astringency retention and sealing, white paeony root astringes yin and blood in the liver, dogwood fruit seals yin and essence in the kidney, and can avoid the stickiness of Jiu steamed rehmannia glutinosa, dogwood fruit essence can also promote yang channel, Chinese angelica can tonify, remove old and regenerate, white paeony root can tonify but not forget to restrain and astringe, donkey-hide gelatin with blood pulp emotion helps the prepared rehmannia glutinosa to nourish yin and enrich the blood, morinda officinalis tonifies the kidney and helps yang to nourish yang and ask yin, dogwood fruit is matched to tonify yang channel, essence can purge, dodder can balance yin and yang of kidney, and has the effect of astringency retention, so that genital essence can be sealed in the kidney for preparation, essence and blood can be mainly tonified, and yang can help half the kidney to help the kidney, so that liver and kidney essence can be filled, and thorough;
teasel root, eucommia bark, largehead atractylodes rhizome, Indian buead, common yam rhizome and the like are all adjuvant drugs, have the effect of assisting essence distribution, tonify kidney, strengthen waist and strengthen fetus, promote diuresis of largehead atractylodes rhizome, benefit waist and navel, strengthen spleen and Indian buead, ensure that spleen and stomach are normally transported, and the medicine can be absorbed by the fine and micro prescription and uploaded to the lung, so that the effects of irrigation, heart transformation and red blood caused by fog and dew can be achieved;
achyranthes root, prepared licorice root and Chinese date are used as guiding drugs, and the achyranthes root has the functions of tonifying the kidney and strengthening the waist, and the prepared licorice root and Chinese date are used for guiding all the drugs to descend to the kidney, Chong and ren uterus and harmonizing the other drugs.
The invention also provides a preparation method of the traditional Chinese medicine compound composition for treating ovarian reserve function decline, which comprises the following steps:
(1) mixing the raw materials, and pulverizing to obtain Chinese medicinal powder;
(2) mixing the raw materials obtained in the step (1), and adding corresponding auxiliary materials into the traditional Chinese medicine powder to prepare the traditional Chinese medicine compound composition.
Preferably, the number of the crushed meshes in the step (1) is 80-100 meshes.
Detailed Description
The present invention will be described in further detail with reference to the following examples, but the scope of the present invention is not limited thereto. In the examples, the starting materials are all common commercial products unless otherwise specified. The experimental procedures described in the examples are not specified, i.e. they are carried out according to conventional experimental procedures.
Example 1
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 30 parts of prepared rehmannia root, 30 parts of Chinese angelica, 30 parts of white paeony root, 15 parts of cornus officinalis, 15 parts of eucommia bark, 25 parts of largehead atractylodes rhizome, 15 parts of tuckahoe, 10 parts of teasel root, 20 parts of honey-fried licorice root, 20 parts of astragalus root, 20 parts of codonopsis pilosula, 15 parts of Chinese date, 10 parts of donkey-hide gelatin, 15 parts of morinda officinalis, 15 parts of dodder, 30 parts of twotooth achyranthes root, 20 parts of Chinese yam and 15 parts of gordon euryale seed.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Example 2
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 30 parts of prepared rehmannia root, 15 parts of Chinese angelica, 15 parts of white paeony root, 15 parts of cornus officinalis, 6 parts of eucommia bark, 15 parts of largehead atractylodes rhizome, 9 parts of tuckahoe, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus root, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of dodder, 10 parts of twotooth achyranthes root, 15 parts of Chinese yam and 10 parts of gordon euryale seed.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Example 3
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 25 parts of prepared rehmannia root, 10 parts of Chinese angelica, 10 parts of white paeony root, 10 parts of cornus officinalis, 5 parts of eucommia bark, 10 parts of largehead atractylodes rhizome, 5 parts of tuckahoe, 5 parts of teasel root, 15 parts of honey-fried licorice root, 15 parts of astragalus root, 10 parts of codonopsis pilosula, 5 parts of Chinese date, 5 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of dodder, 10 parts of twotooth achyranthes root, 10 parts of Chinese yam and 15 parts of gordon euryale.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 1
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 30 parts of prepared rehmannia root, 15 parts of white paeony root, 15 parts of cornus officinalis, 6 parts of eucommia bark, 15 parts of bighead atractylodes rhizome, 9 parts of poria cocos, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus root, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 10 parts of morinda officinalis, 10 parts of achyranthes root, 15 parts of Chinese yam and 10 parts of gorgon fruit.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 2
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 10 parts of prepared rehmannia root, 15 parts of Chinese angelica, 15 parts of white paeony root, 5 parts of cornus officinalis, 6 parts of eucommia bark, 4 parts of largehead atractylodes rhizome, 9 parts of tuckahoe, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus root, 4 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of dodder, 10 parts of twotooth achyranthes root, 15 parts of Chinese yam and 10 parts of gordon euryale seed.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 3
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 30 parts of prepared rehmannia root, 15 parts of ginseng, 15 parts of white peony root, 15 parts of cornus officinalis, 6 parts of eucommia bark, 15 parts of pinellia ternate, 9 parts of poria cocos, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus mongholicus, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of semen cuscutae, 10 parts of akebiaquinata, 15 parts of Chinese yam and 10 parts of semen euryales.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 4
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 30 parts of rehmannia, 15 parts of angelica, 15 parts of white peony root, 15 parts of cornus, 6 parts of parasitic loranthus, 15 parts of bighead atractylodes rhizome, 9 parts of poria cocos, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of cortex acanthopanacis, 10 parts of achyranthes root, 15 parts of Chinese yam and 10 parts of gorgon fruit.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 5
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 10 parts of prepared rehmannia root, 35 parts of Chinese angelica, 15 parts of white peony root, 5 parts of cornus, 20 parts of eucommia bark, 15 parts of bighead atractylodes rhizome, 9 parts of poria cocos, 15 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus, 5 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of semen cuscutae, 10 parts of achyranthes root, 15 parts of Chinese yam and 10 parts of gordon euryale seed.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 6
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 7 parts of honey-fried licorice root, 10 parts of astragalus root, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of semen cuscutae, 10 parts of achyranthes root, 15 parts of Chinese yam and 10 parts of gordon euryale seed.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Comparative example 7
A traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following components in parts by weight: 30 parts of prepared rhizome of rehmannia, 15 parts of angelica, 15 parts of white peony root and 15 parts of cornus fruit.
A preparation method of a traditional Chinese medicine compound composition for treating ovarian reserve function decline comprises the following steps:
(1) mixing the above Chinese medicinal materials, and pulverizing to 80 mesh to obtain mixed Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
Examples of the experiments
A total of 110 patients diagnosed with diminished ovarian reserve function between 30 and 55 years of age were selected, and the 110 patients diagnosed were divided into 11 groups of 10 patients each for clinical trials. Wherein, 1-3 groups of the traditional Chinese medicine compound composition for treating ovarian reserve function decline prepared in the embodiment 1-3 are respectively used for treatment, the dosage of each time is equivalent to 20g of decoction pieces, 3 times a day, and 90 days are totally carried out; 4-7 groups of the traditional Chinese medicine compound compositions prepared in the comparative examples 1-4 for treating the ovarian reserve function decline are respectively used for treatment, the dosage of each time is equivalent to 20g of decoction pieces, 3 times a day, and 90 days are carried out; 8-10 groups take the traditional Chinese medicines in comparative examples 5-7, and 11 groups take dehydroepiandrosterone for conventional treatment, 1mg each time once a day for 90 days.
After the treatment is finished, the perimenopausal symptoms (hot flashes, menstrual disorders, osteoporosis, etc.), menstrual intake, FSH hormone, LH hormone, anti-mullerian hormone and the number of basal antral follicles of the patient are examined to determine the efficacy.
Wherein, the standard for diagnosing the hypofunction of the ovary reserve is perimenopause symptom, small menstrual amount and abnormal clinical test index (FSH is more than 10mlU/mL or FSH/LH is more than 2, anti-mullerian hormone is less than 2ng/mL, and the number of basic antral follicles is less than 5).
In the curative effect level, effective standards are that perimenopausal symptoms are obviously reduced, menstrual volume is obviously increased, clinical test indexes are normal (FSH is less than 10mlU/mL or FSH/LH is less than 2, anti-mullerian hormone is 2-6.5ng/mL, and the number of basic antral follicles is 5-10); the improvement criteria are perimenopausal symptom decline, menstrual volume increase, partial normal clinical test indexes (FSH less than 10mlU/mL or FSH/LH less than 2, anti-mullerian hormone 2-6.5ng/mL, and number of basic antral follicles 5-10); the ineffective criteria are no obvious decline of perimenopausal symptoms, no obvious increase of menstrual volume, abnormal clinical test indicators (FSH > 10mlU/mL or FSH/LH > 2, anti-Mullerian hormone < 2ng/mL, number of basic antral follicles < 5).
TABLE 1 Experimental results of a Chinese medicinal composition for treating ovarian reserve function decline
| Is effective | Improvement of life | Invalidation | High efficiency | Inefficiency of | |
| Example 1 | 10 | 0 | 0 | 100％ | 0％ |
| Example 2 | 9 | 1 | 0 | 100％ | 0％ |
| Example 3 | 9 | 0 | 1 | 90％ | 10％ |
| Comparative example 1 | 1 | 4 | 5 | 50％ | 50％ |
| Comparative example 2 | 2 | 3 | 5 | 50％ | 50％ |
| Comparative example 3 | 6 | 1 | 3 | 70％ | 30％ |
| Comparative example 4 | 7 | 0 | 3 | 70％ | 30％ |
| Comparative example 5 | 3 | 3 | 4 | 60％ | 40％ |
| Comparative example 6 | 2 | 3 | 5 | 50％ | 50％ |
| Comparative example 7 | 3 | 1 | 6 | 40％ | 60％ |
| Dehydroepiandrosterone | 2 | 3 | 5 | 50％ | 50％ |
The experimental results are shown in table 1, and the treatment examples 1-3 using the traditional Chinese medicine compound composition for treating ovarian reserve function decline have the advantages of obvious curative effect, high effective rate of 90-100%, and low ineffective rate of 0-10%; compared with the comparative examples 1-6 which adopt partial drug deletion formulas or replacement drug formulas of the traditional Chinese medicine compound composition for treating the ovarian reserve function decline, the effective rate is reduced to some extent compared with the examples 1-3, the effective rate is 50-70%, the ineffective rate is 30-50%, and the effect is obviously reduced compared with the examples 1-3; compared example 7 using traditional Chinese medicine compound, the treatment effect is further reduced, the effective rate is 40%, and the ineffective rate is 60%; the dehydroepiandrosterone is used for conventional treatment, and the effective rate is 50%; the traditional Chinese medicine compound composition for treating ovarian reserve function decline has a remarkable effect of treating ovarian reserve function decline.
Finally, the above embodiments are only for illustrating the technical solutions of the present invention and not for limiting, although the present invention has been described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions may be made to the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention, and all of them should be covered in the claims of the present invention.
Claims (4)
1. A traditional Chinese medicine compound composition for treating ovarian reserve function decline is characterized by comprising the following components in parts by weight: 25-30 parts of prepared rehmannia root, 10-30 parts of angelica, 10-30 parts of white peony root, 10-15 parts of cornus officinalis, 5-15 parts of eucommia bark, 10-25 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 5-10 parts of teasel root, 15-20 parts of honey-fried licorice root, 15-20 parts of astragalus, 10-20 parts of codonopsis pilosula, 5-15 parts of Chinese date, 5-10 parts of donkey-hide gelatin, 10-15 parts of morinda officinalis, 10-15 parts of dodder, 10-30 parts of achyranthes root, 10-20 parts of Chinese yam and 10-15 parts of gorgon fruit.
2. The traditional Chinese medicine compound composition for treating ovarian reserve function decline according to claim 1, is characterized by comprising the following components in parts by weight: 30 parts of prepared rehmannia root, 15 parts of Chinese angelica, 15 parts of white paeony root, 15 parts of cornus officinalis, 6 parts of eucommia bark, 15 parts of largehead atractylodes rhizome, 9 parts of tuckahoe, 6 parts of teasel root, 7 parts of honey-fried licorice root, 10 parts of astragalus root, 10 parts of codonopsis pilosula, 8 parts of Chinese date, 6 parts of donkey-hide gelatin, 10 parts of morinda officinalis, 10 parts of dodder, 10 parts of twotooth achyranthes root, 15 parts of Chinese yam and 10 parts of gordon euryale seed.
3. The preparation method of the traditional Chinese medicine compound composition for treating the ovarian reserve function decline as claimed in claim 1 or 2, which is characterized by comprising the following steps:
(1) mixing the raw materials, and pulverizing to obtain Chinese medicinal powder;
(2) and (2) adding corresponding auxiliary materials into the traditional Chinese medicine powder obtained in the step (1) to prepare the traditional Chinese medicine compound composition.
4. The preparation method of the traditional Chinese medicine compound composition for treating ovarian reserve function decline according to claim 3, wherein the number of the crushed meshes in the step (1) is 80-100 meshes.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011568244.1A CN112618644B (en) | 2020-12-25 | 2020-12-25 | Traditional Chinese medicine compound composition for treating ovarian reserve function decline and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011568244.1A CN112618644B (en) | 2020-12-25 | 2020-12-25 | Traditional Chinese medicine compound composition for treating ovarian reserve function decline and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112618644A true CN112618644A (en) | 2021-04-09 |
| CN112618644B CN112618644B (en) | 2022-09-09 |
Family
ID=75325181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011568244.1A Active CN112618644B (en) | 2020-12-25 | 2020-12-25 | Traditional Chinese medicine compound composition for treating ovarian reserve function decline and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112618644B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113398078A (en) * | 2021-08-03 | 2021-09-17 | 山西黄河中药有限公司 | Granular traditional Chinese medicine for improving ovarian reserve function and preparation method thereof |
| CN114699474A (en) * | 2021-12-24 | 2022-07-05 | 宁波市第一医院 | Traditional Chinese medicine composition for treating ovarian reserve function reduction and application thereof |
| CN115463177A (en) * | 2021-10-09 | 2022-12-13 | 成都中医药大学附属医院 | Traditional Chinese medicine composition for treating ovarian hypofunction and/or fallopian tube blockage |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119131A1 (en) * | 2007-04-02 | 2008-10-09 | Medcina Group Pty Ltd | Herbal compositions and methods for treating female infertility |
| CN104888175A (en) * | 2015-06-25 | 2015-09-09 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treatment of Yang-deficiency and cold-blood type diminished ovarian reserve function |
| CN106620492A (en) * | 2017-02-07 | 2017-05-10 | 付曙光 | Ointment for treating degrading of ovarian reserve function and preparation method thereof |
-
2020
- 2020-12-25 CN CN202011568244.1A patent/CN112618644B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008119131A1 (en) * | 2007-04-02 | 2008-10-09 | Medcina Group Pty Ltd | Herbal compositions and methods for treating female infertility |
| CN104888175A (en) * | 2015-06-25 | 2015-09-09 | 济南邦文医药科技有限公司 | Traditional Chinese medicine for treatment of Yang-deficiency and cold-blood type diminished ovarian reserve function |
| CN106620492A (en) * | 2017-02-07 | 2017-05-10 | 付曙光 | Ointment for treating degrading of ovarian reserve function and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 任仕洪: "安任固冲汤治疗先兆流产52例", 《新中医》 * |
| 彭芷美: "八珍汤加川杜仲、菟丝子促优生浅探", 《江西中医学院学报》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113398078A (en) * | 2021-08-03 | 2021-09-17 | 山西黄河中药有限公司 | Granular traditional Chinese medicine for improving ovarian reserve function and preparation method thereof |
| CN113398078B (en) * | 2021-08-03 | 2022-05-20 | 山西黄河中药有限公司 | Granular traditional Chinese medicine for improving ovarian reserve function and preparation method thereof |
| CN115463177A (en) * | 2021-10-09 | 2022-12-13 | 成都中医药大学附属医院 | Traditional Chinese medicine composition for treating ovarian hypofunction and/or fallopian tube blockage |
| CN115463177B (en) * | 2021-10-09 | 2023-11-17 | 成都中医药大学附属医院 | Traditional Chinese medicine composition for treating hypofunction of ovary and/or oviduct blockage |
| CN114699474A (en) * | 2021-12-24 | 2022-07-05 | 宁波市第一医院 | Traditional Chinese medicine composition for treating ovarian reserve function reduction and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112618644B (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112618644B (en) | Traditional Chinese medicine compound composition for treating ovarian reserve function decline and preparation method thereof | |
| CN108324821B (en) | Traditional Chinese medicine composition with effect of inducing follicular development and application thereof | |
| CN111568987A (en) | Medicine for treating anovulatory infertility | |
| Xu et al. | Application of traditional Chinese medicine in the treatment of infertility | |
| CN113855771B (en) | A Chinese medicinal composition for treating ovarian reserve function decline disease | |
| CN101543622B (en) | Chinese medicament series for treating anovulatory infertility | |
| CN116763888B (en) | Traditional Chinese medicine composition for improving follicular development and ovum quality in controlled hyperstimulation period and application thereof | |
| CN111317802B (en) | Traditional Chinese medicine decoction for treating ovulation disorder type infertility | |
| CN114177256B (en) | Traditional Chinese medicine composition for treating ovarian reserve hypofunction and application thereof | |
| CN105456515A (en) | Traditional Chinese medicine effective part composition for woman progestation conditioning and preparation method thereof | |
| CN111317777B (en) | Traditional Chinese medicine decoction for treating kidney deficiency and phlegm dampness type polycystic ovarian syndrome infertility | |
| CN103479859B (en) | Traditional Chinese medicine composition for treating hyperandrogenism of polycystic ovary syndrome | |
| CN105943758A (en) | Traditional Chinese medicine composition for treating infertility and application of traditional Chinese medicine composition | |
| CN104587408A (en) | New use of Qilin pills | |
| CN116211947B (en) | Traditional Chinese medicine composition with function of improving endometrial receptivity and application thereof | |
| CN111481614A (en) | Application of Wubi yam pills in preparation of medicine for treating perimenopausal syndrome | |
| CN105944020A (en) | Traditional Chinese medicine for treating ovarian function decrease | |
| CN111249395A (en) | Traditional Chinese medicine composition for increasing egg cytoplasm quantity and preparation method and application thereof | |
| CN115212265B (en) | Chinese patent medicine for treating polycystic ovary syndrome | |
| CN106620492A (en) | Ointment for treating degrading of ovarian reserve function and preparation method thereof | |
| CN114306534A (en) | Composition for treating polycystic ovarian syndrome, preparation method and application | |
| CN103099957A (en) | Drug capsule capable of tonifying kidney and producing sperm and preparation method of drug | |
| Yang et al. | Exploring the thought of TCM prevention and treatment of small follicle ovulatory infertility from the theory of spleen and stomach | |
| CN105535393A (en) | Chinese herbal preparation for treating male infertility | |
| CN104069314A (en) | Sperm tonifying soup |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220803 Address after: 350001 No. 18, daoshan Road, Gulou District, Fuzhou City, Fujian Province Applicant after: FUJIAN MATERNAL AND CHILD CARE SERVICE CENTRE Address before: 611130 No.1166, east section of Liucheng Liutai Avenue, Wenjiang District, Chengdu City, Sichuan Province Applicant before: Li Wanjing |
|
| TA01 | Transfer of patent application right | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |